-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 9, Obsidian Therapeutics announced the completion of a US$115 million Series B financing
TIL is a tumor-infiltrating lymphocyte isolated from a patient's tumor tissue, which is expanded in vitro and then infused back into the patient's body
cytoTIL15 is Obsidian's leading cytoTIL project and is currently in the preclinical development stage for the treatment of metastatic melanoma and other solid tumors
▲Obsidian's cytoTIL project pipeline (picture source: Obsidian official website)
Reference materials:
[1] Obsidian Therapeutics Announces Closing of $115 Million Series B Financing.